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ABSTRACT
Cancer stem cells (CSCs) may represent targets for carcinogenic initiation by 
chemical and environmental agents. Recent studies have raised a concern over the 
potential carcinogenicity of carbon nanotubes (CNTs), one of the most commonly used 
engineered nanomaterials with asbestos-like properties. Here, we show that chronic 
(6-month) exposure of human lung epithelial cells to single-walled (SW) CNTs at the 
workplace-relevant concentration induced an emergence of lung CSCs, as indicated 
by the induction of CSC tumor spheres and side population (SP). These CSCs, which 
were found to overexpress tumor promoter caveolin-1 (Cav-1), displayed aggressive 
cancer phenotypes of apoptosis resistance and enhanced cell invasion and migration 
compared with their non-CSC counterpart. Using gene manipulation strategies, we 
reveal for the first time that Cav-1 plays an essential role in CSC regulation and 
aggressiveness of SWCNT-transformed cells partly through p53 dysregulation, 
consistent with their suggested role by microarray and gene ontology analysis. Cav-
1 not only promoted tumorigenesis in a xenograft mouse model but also metastasis 
of the transformed cells to neighboring tissues. Since CSCs are crucial to the initiation 
and early development of carcinogenesis, our findings on CSC induction by SWCNTs 
and Cav-1 could aid in the early detection and risk assessment of the disease. 
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
death, and environmental and occupational exposure 
is a major cause of most cases [1,2]. Evolving research 
in stem cells and cancer biology have provided strong 
evidence for the existence of cancer stem cells (CSCs) in 
various human solid tumors, including brain, breast, bone 
marrow, prostrate, colon, and lung [3,4]. These CSCs are 
potential driving force of tumor initiation and progression 
due to their self-renewal and tumorigenic properties 
[5,6]. Induction of CSCs from non-tumorigenic cells may 
initiate carcinogenesis. While carcinogenesis induced by 
various chemicals and environmental agents including 
cigarette smoke, air pollution, and heavy metals has been 
extensively studied [7−9], relatively little has been carried 
out or known about the cancer risk caused by nanomaterial 
exposure, notably carbon nanotubes (CNTs) which share 
similar properties with asbestos fibers, a known human 
carcinogen [10−13]. Identifying CSC induction and its 
regulation by CNTs might lead to a better understanding 
of CNT carcinogenesis.
Typical developmental period for fiber-induced lung 
cancer in humans is 30-40 years [14]. The present study 
was undertaken to investigate whether chronic exposure of 
human lung epithelial cells to CNTs can induce CSCs, and 
if so by what mechanisms. Recently, a number of proteins 
have been identified to have a high prognostic correlation 
with lung cancer. Among these, a plasma membrane-
associated protein caveolin-1 (Cav-1) has gained a 
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considerable attention, since its expression has been 
linked to the advanced stages of squamous and non-small 
cell lung cancers [15−17]. Poor prognosis and reduced 
disease-free and overall survival were observed in Cav-
1-positive patients [16]. Experimentally, an up-regulation 
of Cav-1 was shown to potentiate various steps in tumor 
progression, metastasis and chemoresistance [18,19], 
anchorage-independent growth (anoikis resistance) 
[20,21], and cell migration and invasion [22,23]. 
Here, we demonstrate that single-walled (SW) 
CNTs can trigger lung epithelial cells to initiate CSCs, 
which exhibit aggressive cancer behaviors of apoptosis 
resistance and enhanced cell motility. These CNT-derived 
CSCs overexpressed Cav-1 which was investigated in this 
study for its role in CSC regulation and tumorigenesis 
using gene manipulation and murine xenograft strategies. 
Our results indicate a novel role of Cav-1-p53 axis 
in CSC regulation, which could be important in lung 
tumorigenesis and metastasis. 
RESULTS
Chronic SWCNT exposure induces CSCs
We have previously shown that chronic exposure of 
human lung epithelial cells to non-cytotoxic concentration 
of SWCNTs induced malignant transformation as 
assessed by soft-agar colony formation, a common 
measure of anchorage-independent growth, and mouse 
xenograft tumorigenesis assays [12]. However, the 
fundamental understanding and regulatory mechanisms 
of tumorigenesis are not well understood. In this study, 
we first showed that SWCNT-induced malignant 
Figure 2: Isolated CSCs display typical CSC 
characteristics. (A) Intrinsic ABCG2 protein expression in 
control BC and SWCNT-exposed BSW cells was determined 
by Western blotting. (B) CSCs and their non-CSC counterpart 
were isolated from BSW cells based on their SP phenotype 
using FACS and designated as SP and NSP cells, respectively. 
Fluorescence analysis of Hoechst 33342 blue uptake in SP and 
NSP cells using fluorescence microscopy (left). Arrows indicate 
the ring-shaped staining pattern in SP cells. Quantitative analysis 
of the Hoechst blue fluorescence is shown (right). (C, D) 
Analysis of tumor sphere (C) and soft agar colony formation (D) 
in SP and NSP cells after two weeks of culture. 
Figure 1: SWCNTs induce CSCs from human lung 
epithelial cells. (A, B) Non-tumorigenic lung epithelial BEAS-
2B cells were continuously exposed to SWCNTs for 6 months, 
then cultured in SWCNT-free medium for more than 20 passages, 
and designated as BSW cells. After which they were analyzed 
for soft agar colony formation (A) and tumor sphere formation 
(B). Passage-matched control BC cells were grown in the same 
background level of dispersant. (C) Analysis of side population 
(SP) in BC, BSW, and H460 lung cancer cells in the presence or 
absence of fumitremorgin c (FTC) using FACS. SP cells (box) 
were determined by their disappearance in the presence of FTC 
and were plotted as a percentage of pool population. (D) CD133 
protein expression in BC, BSW, and H460 cells was determined 
by Western blotting. β-actin was used as a loading control. Data 
are mean ± SD (n = 3 or 4). *p < 0.05 vs. control BC cells.
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transformation was irreversible, since cells that were 
propagated for more than 20 passages in the absence of 
SWCNTs still maintained the ability to grow on soft agar 
(Figure 1A). We next tested whether chronic SWCNT 
exposure can induce CSCs, a subpopulation that may drive 
tumor initiation and progression. Fundamental properties 
of CSCs are their ability to self-renew and generate 
differentiated progeny [24,25]. Tumor sphere assay under 
non-attached and serum-starved conditions was used to 
determine the CSC self-renewal capability. Figure 1B 
shows that while passage-control BC cells minimally 
survived, chronic SWCNT-exposed BSW cells formed 
large floating spherical colonies. These results suggest 
the existence of cells that possess the characteristics of 
CSCs and their acquisition from non-tumorigenic lung 
epithelial cells by SWCNTs. The BSW cells that were 
passaged from first-generation tumor spheres preserved 
the ability to form second-generation spheres (not shown), 
thus confirming their renewal and repopulation capability.
The ability to efflux Hoechst dye via the multidrug 
resistance transporter ATP-binding cassette sub-family 
G member 2 (ABCG2) as identified by side population 
(SP) has proven to be a valuable marker for CSCs from 
various solid tumors and cancer cell lines [4,24,26]. 
Chronic SWCNT-exposed BSW cells and passage-
control BC cells were stained with Hoechst 33342 in the 
presence or absence of fumitremorgin C (FTC), a specific 
inhibitor of ABCG2 transporter. SP cells, which disappear 
in the presence of FTC, were identified by FACS and 
Figure 3: Tumor initiating capability of isolated CSCs. 
Isolated SP and NSP cells derived from chronic SWCNT-
exposed BSW cells were subcutaneously injected into the left 
and right flanks of NSG mice at the injection dose of 5×104 cells/
flank. (A) SP and NSP tumors at 28 days. (B) Tumor incidence 
and weight of SP, NSP and BC cells are shown. 
Figure 4: Isolated CSCs display aggressive cancer 
phenotypes. (A, B) Isolated SP and NSP cells derived from 
chronic SWCNT-exposed BSW cells were analyzed for cell 
migration (A) and invasion (B) at 48 hours after incubation. (C) 
Acquired apoptosis resistance of SP cells to TNF-α (150 ng/mL) 
as compared to NSP cells at 24 hours. Data are mean ± SD (n = 
4). *p < 0.05 vs. SP cells. 
Figure 5: Genome-wide transcription profiles of chronic 
SWCNT-exposed BSW cells compared to the control BC 
cells. (A) Volcano plot of differentially expressed genes (DEGs) 
comparing BSW and BC cells. Red point represents DEGs with 
fold change ≥ 2 and p ≤ 0.05. (B) Gene ontology analysis of 
top-ranked diseases, functions, and upstream regulators based 
on p-value. 
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calculated as a proportion (percentage) of the pool 
population. The results show that the SP fraction of BSW 
cells was substantially higher than that of the BC cells 
(~15% vs. 3%), and was comparable to that of the well-
established non-small cell lung carcinoma H460 cells, 
which served as a positive control in this study (Figure 
1C). As an additional measure to substantiate the existence 
of CSCs, we determined CD 133 expression, one of the 
key biomarkers of lung CSCs [27,28], in BC, BSW, and 
H460 cells. Figure 1D shows that CD133 expression 
was high in BSW and H460 cells, but not in BC cells. 
Altogether, these results supported the notion that BSW 
cells were enriched with CSCs. 
SP cells display CSC properties 
FACS enables the isolation of CSCs from their 
parental cells based on their SP phenotype. To first ensure 
the basis of SP analysis, we determined the expression 
level of ABCG2 transporter in BSW cells in comparison 
with control BC cells. As depicted in Figure 2A, ABCG2 
expression was highly upregulated in BSW cells. We then 
isolated CSCs and their non-CSC counterpart from BSW 
cells using FACS and designated them as SP and non-SP 
(NSP) cells, respectively. To validate the stem phenotype 
of the isolated cells, we assessed their Hoechst dye uptake 
characteristic using fluorescence microscopy. Figure 2B 
shows that Hoechst fluorescence intensity was less in the 
SP compared to NSP cells. We also observed a staining 
Figure 6: Cav-1 is a potential regulator of tumorigenesis and metastasis. (A) Network analysis for the biofunctions of tumorigenesis 
of cells and metastasis of lung cells based on DEG profiles. Yellow and blue indicate overexpressed and underexpressed genes, respectively, 
while intensity indicates magnitude of fold change. Orange dash lines indicate predicted activation of the biofunctions based on expression 
direction. (B) Tumorigenesis and metastasis promoting gene signaling network (GSN). DEGs that promote tumorigenesis of cells and 
metastasis of lung cells were included in the GSN. Genes were mapped with known direct (solid lines) and indirect (dash lines) signaling 
associations using IPA. Arrow direction indicates the direction of relationship. 
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pattern that we called ring-shape pattern in the SP cells 
(Figure 2B-arrows), in which the Hoechst dye cannot 
completely stain SP nuclei, indicating their ability to 
efflux the dye. We next subjected freshly isolated SP and 
NSP cells to tumor sphere and soft agar assays, the gold 
standards for assessing CSC and malignant properties. The 
results indicated that the SP cells formed larger and greater 
number of spheres and colonies than the NSP cells (Figure 
2C and D), indicating their CSC features and validity of 
the CSC isolation. The observation that the NSP cells 
which accounted for the vast majority of sorted cells but 
lacked substantial ability to form tumor colonies suggested 
the role of SP cells (CSCs) as tumor-initiating cells. The 
greater tumorigenicity of SP cells was subsequently 
confirmed in vivo using a xenograft mouse model, where 
they exhibited greater tumor incidence, size, and volume 
(Figure 3A and B).
SP cells display an aggressive cancer behavior 
The aggressive neoplastic behavior of CSCs was 
assessed by cell migration, invasion, and apoptosis 
assays. Freshly isolated SP and NSP cells were seeded 
onto Transwell chambers with control inserts (migration) 
or Matrigel-coated inserts (invasion) and incubated for 48 
hours. The results showed that the SP cells exhibited a 
significant increase in migration and invasion activities as 
compared to NSP cells (Figure 4A and B). This increase 
in cellular activities was not due to the difference in cell 
growth since the growth rate of SP and NSP cells was 
comparable at 48 hours as determined by MTT assay (data 
Figure 7: Effects of chronic SWCNT exposure on ROS 
targeted proteins. (A) The effects of SWCNTs on ROS 
generation of lung epithelial BC cells using H2DCF-DA as 
a fluorescent probe. Cells were treated with varying doses 
of SWCNTs (0-0.15 μg/cm2) in the presence or absence of 
antioxidant NAC (5 mM) for 3 hours (left) or with SWCNTs 
(0.15 μg/cm2) for various times (0-4 hours) (right). (B) Isolated 
SP and NSP cells derived from chronic SWCNT-exposed 
BSW cells were analyzed for tumor suppressor p53 and tumor 
promoter Cav-1 protein expression using Western blotting in 
comparison with their passage-matched control BC cells. β-actin 
was used as a loading control. The intensity of p53 and Cav-1 
bands was normalized to that of β-actin. Relative intensity level 
was then calculated by dividing the normalized intensity of each 
sample by that of the control, i.e. in BC cells. (C) BSW cells 
were stably transfected with empty vector (Ctrl), p53 and Cav-
1 plasmids as described in Materials and methods. Analysis of 
side population (SP) in BSW-Ctrl, BSW-p53 and BSW-Cav-1 
cells using FACS. SP cells (box) were determined by their 
disappearance in the presence of FTC and were plotted as a 
percentage of pool population. Data are mean ± SD (n = 3). §p 
< 0.05 vs. untreated BC cells. †p < 0.05 vs. SWCNT-treated BC 
cells (0.15 μg/cm2). *p < 0.05 vs. vector-transfected BSW-Ctrl 
cells. #p < 0.05 vs. SP cells. 
Figure 8: Cav-1 regulates p53 expression. (A) Analysis of 
tumor spheres in BSW-Ctrl, BSW-p53 and BSW-Cav-1 cells 
after two weeks of culture. (B) Cell migration assays of BSW-
Ctrl, BSW-p53 and BSW-Cav-1 cells at 48 hours after incubation. 
(C) Effect of Cav-1 overexpression on p53 expression. Cav-1 
and p53 expression in BSW-Ctrl and BSW-Cav-1 cells were 
determined by Western blotting. β-actin was used as a loading 
control. (D) Cav-1 knockdown experiments were performed 
using Cav-1 shRNA (shCav-1) and Cav-1 and p53 expression 
in BSW-shCtrl (vector) and BSW-shCav-1 cells were analyzed 
by Western blotting. Data are mean ± SD (n = 3). *p < 0.05 vs. 
vector-transfected BSW-Ctrl or BSW-shCtrl cells. 
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not shown). We next compared the apoptosis resistance 
of SP and NSP cells in response to TNF-α, a known 
apoptosis inducer of BC cells [12]. Figure 4C shows that 
TNF-α induced less apoptosis in the SP than NSP cells as 
demonstrated by their reduced nuclear condensation and 
fragmentation. These results indicate that CSCs acquired 
enhanced cell motility and apoptosis resistance, which are 
important in tumorigenesis and metastasis.
Gene profiling identifies Cav-1 as an important 
regulator of tumorigenesis and metastasis
To gain a better insight into the mechanisms 
underlying the phenotypic changes of chronic SWCNT-
exposed BSW cells, we compared the genome-wide 
transcription profiles of BSW cells and their passage-
control BC cells using microarray analysis. We identified 
1932 differentially expressed genes (DEGs) between 
BSW and BC cells with fold change ≥ 2 and p-value ≤ 
0.05, of which 693 genes were upregulated and 1239 
genes were downregulated, as shown as red points in the 
volcano plot (Figure 5A). Gene ontology analysis using 
Ingenuity Pathway Analysis (IPA; Qiagen, Redwood City, 
CA) revealed cancer as a top-ranked disease, cell growth/
proliferation as a top-ranked cellular function, and TP53, 
the most frequently altered gene in human cancers [29], 
as a top-ranked upstream regulator (Figure 5B). These 
results are consistent with our functional assays showing 
that BSW cells possess aggressive tumorigenic properties. 
To determine the potential regulator(s) of 
tumorigenesis and metastasis, which are important 
features of CSCs, we performed IPA functional analysis 
of tumorigenesis (p-value 8.74×10-4) and metastasis of 
lung cells (p-value 8.00×10-4) based on their DEG profiles. 
Figure 6A shows that CAV1, with an approximately 2.5-
fold increase in BSW cells, is a dominant molecule for 
both networks. Tumorigenesis and metastasis-promoting 
gene signaling network (GSN) showed that CAV1 
occupied a focal position of the GSN, while other hub 
genes with first order linkage to CAV1 include MYC, 
CCND1, IL6, and FN1 (Figure 6B). These findings 
indicate the importance of CAV1 in BSW tumorigenesis 
and metastasis, which may be associated with the CSCs. 
Oxidative stress, the second top-ranked toxicological 
responses on the IPA (p-value 2.53×10-5), has been shown 
to be induced in the tumor microenvironment [30,31] and 
has been suggested to play a vital role in tumorigenesis 
and metastasis [32,33]. Here we show that treatment of 
the cells with SWCNTs (0-0.15 μg/cm2) induced a dose- 
and time-dependent increase in cellular DCF fluorescence, 
an indicator of cellular ROS generation and oxidative 
stress, in BC cells (Figure 7A). An addition of antioxidant 
N-acetylcysteine (NAC, 5mM) inhibited the oxidative 
effect of SWCNTs (0.15 μg/cm2) (Figure 7A-left), thus 
confirming the induction of ROS by SWCNTs.
Role of p53 and Cav-1 in CSC induction
To understand the underlying mechanisms of CSC 
induction by SWCNTs, we investigated the potential 
role of p53 and Cav-1 since they are known regulators of 
lung carcinogenesis [34,35] and are key targets of ROS 
[21,22,36]. Their potential role in BSW tumorigenesis 
was also suggested by IPA. Figure 7B shows that p53 was 
strikingly downregulated in SP cells with the rank order 
of expression being BC > NSP > SP. In contrast, Cav-1 
expression was highest in the SP cells followed by NSP 
and BC cells (SP > NSP > BC). To further investigate 
the functional role of p53 and Cav-1 in CSC induction, 
we manipulated their expression by gene transfection in 
chronic SWCNT-exposed BSW cells and studied their 
Figure 9: Cav-1 promotes tumor growth and progression 
in vivo. BSW-Ctrl and BSW-Cav-1 cells were genetically 
labeled with luciferase and subcutaneously injected into the 
left and right flanks of NSG mice at the injection dose of 3×105 
cells/flank. (A) Representative sequences of bioluminescence 
images of mice from BSW-Ctrl and BSW-Cav-1 cells taken at 
the time of inoculation (week 0) and 3-5 weeks post-injection. 
(B) Quantitative analysis of tumor bioluminescence signals over 
time. (C) Normalization of tumor signals at various times to their 
initial signal at week 0. (D) Subcutaneous tumors were dissected 
and weighed at 5 weeks post-injection. (E) (a) Representative 
sequences of bioluminescence images of mice and dissected 
subcutaneous tumors. (b, c) Representative H&E micrographs 
of subcutaneous tumors (b) and neighboring muscle tissues (c). 
Data are mean ± SD (n = 4 or 6). *p < 0.05 vs. vector-transfected 
BSW-Ctrl cells.
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effect on SP phenotype. Stably transfected cells were 
stained with Hoechst 33342 in the presence or absence of 
ABCG2 inhibitor FTC, and SP fractions were determined 
as earlier described. Figure 7C shows that overexpression 
of p53 significantly inhibited SP, whereas overexpression 
of Cav-1 promoted SP as compared to parental BSW cells. 
These results indicate the involvement of p53 and Cav-1 in 
the CSC acquisition of SWCNT-treated cells.
To confirm the role of p53 and Cav-1 in CSC 
regulation, tumor sphere formation assays were performed 
on the genetically manipulated cells. Figure 8A shows that 
the p53-overexpressing cells formed smaller and fewer 
number of tumor spheres, while the Cav-1-overexpressing 
cells exhibited larger and greater number of tumor spheres 
as compared to vector-transfected BSW control cells, thus 
validating the inhibitory role of p53 and the promoting 
role of Cav-1 in the CSC induction by SWCNTs. 
Role of p53 and Cav-1 in cell aggressiveness
Having shown that the CSCs acquired aggressive 
cancer phenotypes, we determined whether overexpression 
of p53 and Cav-1 affect cell aggressiveness by analyzing 
cell migration using Transwell migration assay. Figure 
8B shows that cell migration was substantially reduced 
in p53-overexpressing cells as compared to vector-
transfected control cells, while Cav-1-overexpressing 
cells exhibited increased migratory activity. These results 
indicate the role of p53 and Cav-1 in cell aggressiveness 
and strengthen their role in CSC regulation.
Regulation of p53 by Cav-1 in SWCNT-treated 
cells
Previous studies showed that an increased 
expression of Cav-1 abrogated p53 activation in breast 
cancer cells induced by cell detachment through an up-
regulation of insulin-like growth factor I (IGF-I) receptor 
[37]. In this study, we similarly observed the inverse 
correlation between Cav-1 and p53 in SP and NSP cells 
(Figure 7B). To test the potential regulatory axis of the 
two molecular regulators in controlling CSC induction, 
we genetically altered Cav-1 expression in BSW cells 
by stable gene transfection and studied its effect on p53 
expression. Figure 8C shows that an overexpression 
of Cav-1 resulted in a decrease in p53 expression as 
compared to control-transfected cells. To confirm the 
above finding, gene knockdown experiments were 
conducted in BSW cells. The cells were transfected with 
Cav-1 shRNA viral particles and analyzed for Cav-1 and 
p53 expression. Figure 8D shows that as compared to 
control-transfected cells, the shCav-1-transfected cells 
exhibited substantially higher p53 expression. Together, 
these results indicate Cav-1 as a negative regulator of p53 
in BSW cells. 
Cav-1 promotes tumor growth and progression in 
vivo
To confirm the role of Cav-1 in the tumorigenicity 
of BSW cells, we assessed tumor growth and progression 
in vivo using a xenograft mouse model. To link Cav-1 to 
CSC regulation, we transfected the parental BSW cells, 
which express a low level of Cav-1 relative to their CSC 
subpopulation, with Cav-1 or control plasmid. Cav-1-
overexpressing and control-transfected cells were then 
genetically labeled with luciferase (Capital Biosciences, 
Rockville, MD) and subcutaneously injected into NSG 
mice at 3×105 cells/flank. Injection of the control BC cells 
at the same (3×105 cells) or higher (1×106 cells) doses 
did not induce tumor formation in NSG mice (data not 
shown). Tumor growth was monitored weekly by using 
IVIS® bioluminescence imaging. By three weeks post-
injection, the tumor luminescence was strikingly higher 
in mice bearing Cav-1-overexpressing cells as compared 
to control cells (Figure 9A), indicating the positive 
regulatory role of Cav-1 on tumor growth. Quantitative 
analysis of the tumor luminescence signals over time 
was shown in Figure 9B. For comparison, these signals 
were normalized to their initial signals at the time of 
inoculation (week 0). Figure 9C shows that the tumor 
signals were significantly higher in mice bearing Cav-1-
overexpressing cells at 3 and 4 weeks post-injection. The 
maximum of approximately 4-fold tumor induction was 
observed with Cav-1-overexpressing cells over control 
cells, substantiating the tumor promoting role of Cav-1. At 
the end of the experiment (week 5), subcutaneous tumors 
were dissected and tumor weight was compared between 
groups. The greater weight of Cav-1-overexpressing 
tumors further supported Cav-1 as a positive regulator 
of tumorigenesis (Figure 9D). Histological analysis of 
subcutaneous Cav-1-overexpressing tumors by H&E 
staining showed a classical cancer cell morphology 
including the condensation of heterochromatin and the 
presence of multinucleated cells, an indicator of mitotic 
dysfunction (Figure 9E-b).
Interestingly, we observed a remarkable tumor 
bioluminescence in mice bearing Cav-1-overexpressing 
cells after the dissection of subcutaneous tumors (Figure 
9E-a). Histological analysis of neighboring muscle tissues 
showed metastatic cells in the muscle tissues of mice 
bearing Cav-1-overexpressing cells (Figure 9E-c). This 
result indicates metastasis of Cav-1-overpressing cells to 
neighboring tissues, which is consistent with the in vitro 
result showing the increased aggressiveness of cells by 
Cav-1 (Figure 8B), and suggests an important role of Cav-
1 in tumor metastasis. 
DISCUSSION
This study addresses human lung cancer risks 
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associated with chronic pulmonary exposure to CNTs. 
We report here that chronic exposure of non-tumorigenic 
human lung epithelial cells to SWCNTs, a major form of 
engineered CNTs, can directly initiate the formation of 
lung CSCs, as indicated by tumor sphere and SP assays 
(Figure 1). The acquisition of these CSCs is important 
for their malignant and aggressive properties. This 
conclusion is based on the observations that the isolated 
CSCs (SP cells) formed much larger colonies and spheres 
under soft agar and tumor sphere assays (Figure 2), had 
greater tumor-initiating capability in vivo (Figure 3), and 
possessed increased migratory and invasive activities as 
well as apoptosis resistance phenotype as compared to 
non-CSCs (NSP cells) (Figure 4). Consistent with this 
finding, a recent study similarly reported the acquisition 
of stem-like properties by lung epithelial cells chronically 
exposed to tobacco and arsenic carcinogens [38,39] with 
enhanced cell motility [38]. Thus, these results may 
reflect common cellular responses to chronic carcinogen 
exposure. 
ROS are known to play a key role in tumor 
development as they may cause damage to DNA, 
RNA and proteins, leading to changes in chromosome 
instability, gene mutation and altered gene expression 
[32]. SWCNTs induced a significant level of ROS, the 
effect of which inhibited by antioxidant NAC (Figure 7A). 
In response to chronic SWCNT exposure, we observed the 
striking alterations of tumor regulators and ROS targeted 
proteins, including downregulation of tumor suppressor 
p53 and upregulation of tumor promoter Cav-1 (Figure 
7B), consistent with their suggested role by IPA gene 
ontology analysis. Using gene manipulation, we revealed 
for the first time the involvement of p53 and Cav-1 in CSC 
acquisition and cell aggressiveness induced by SWCNTs 
(Figure 7C, 8A and B). It has been recently demonstrated 
that wild-type p53 positively regulated cell differentiation 
in breast cancer cells and loss of p53 favored CSC growth 
[40,41]. However, the functional role of Cav-1 in CSC 
induction is not known. Our study provides the first 
initial evidence for the tumor promoting activity of Cav-1 
through CSC regulation. Furthermore, we found that Cav-
1 acts upstream of p53 in mediating the effect (Figure 8C 
and D). Overexpression of Cav-1 leads to p53 inactivation 
in the tested cell system, consistent with the earlier finding 
in breast cancer cells [35]. By contrast, p53 was activated 
upon Cav-1 inhibition by shRNA knockdown. In addition 
to the regulatory role of ROS in Cav-1 expression [22], 
the feedback antioxidant function of Cav-1 was reported 
in human lung cancer cells [42]. As p53 activation is 
generally triggered by ROS [34], it is plausible that the 
observed p53 inactivation may result from the antioxidant 
effect of Cav-1. Cav-1 and p53 may form a regulatory axis 
that regulates CSCs through c-Myc, one of the original 
stem cell reprogramming factors [43,44] and a proto-
oncogene [45]. Tumorigenesis and metastasis promoting 
GSN revealed MYC overexpression and its first order 
linkage to CAV1 (Figure 6B). Cav-1 overexpression 
and inhibition have previously shown to mediate c-Myc 
level in prostate cancer cell lines through the interaction 
between Cav-1 and low-density lipoprotein receptor-
related protein 6 (LRP6) [46]. Likewise, c-Myc is a 
known downstream target of p53 at the transcriptional and 
posttranscriptional levels [47,48]. With its unique structure 
of lipid microdomains, Cav-1 interacts with multidrug 
resistance ABCG2 transporter protein and regulates its 
transporting activity [49,50]. As SP phenotype of CSCs is 
attributed to the expression of ABCG2, it is plausible that 
Cav-1 might also regulate CSCs through ABCG2 protein. 
Having demonstrated that Cav-1 contributed to CSC 
regulation and malignancy induced by chronic SWCNT 
exposure in vitro, we determined the role of Cav-1 in 
tumor growth and progression in vivo. Our data showed 
that Cav-1 not only promoted tumor formation but also 
metastasis of the tumor cells to neighboring tissues (Figure 
9). The tumor-promoting effect of Cav-1 in SWCNT-
transformed cells is similar to that observed in human 
lung cancer cell lines [51], indicating a potential shared 
mechanism between laboratory SWCNT-driven tumors 
and human lung cancer. 
In conclusion, this study demonstrated that 
SWCNTs are capable of inducing CSCs and tumorigenesis 
in a xenograft mouse model. This study also unveiled 
the positive regulatory role of Cav-1 in the tumorigenic 
process. This protein is overexpressed in chronic SWCNT-
exposed lung cells, particularly in the CSC subpopulation, 
and is a key contributing factor to the malignant and 
aggressive properties of the cells. Cav-1 acts upstream of 
p53 resulting in its inactivation, the event that is common 
in most human cancers [27]. By linking Cav-1, CSCs and 
tumorigenesis, we documented a novel mechanism of 
Cav-1 that drives SWCNT tumorigenesis possibly through 
CSC acquisition. As induction of CSCs is an early event 
in carcinogen-induced pre-malignancy [38], detection of 
Cav-1 might aid in the early diagnosis and prevention of 
CNT-induced lung carcinogenesis.
MATERIALS AND METHODS 
CNT characterization and preparation
SWCNTs were obtained from Carbon 
Nanotechnology (CNI, Houston, Texas) and were 
purified by acid treatment to remove metal contaminates. 
Elemental analysis by nitric acid dissolution and inductive 
coupled plasma-atomic emission spectrometry (ICP- 
AES) showed that the purified SWCNT contained 99% 
elemental carbon and less than 1% of contaminants. The 
metal residues were mostly iron (Fe) at 0.23% by weight. 
The surface area, length, and width of individual dry 
SWCNT were 400-1040 m2/g, 0.6 ± 0.5 μm, and 1 ± 0.2 
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nm (W), respectively [52]. SWCNTs were dispersed by 
using acetone/sonication method as previously described 
[12]. 
Chemicals and reagents
Hoechst 33342, N-acetyl cysteine (NAC), 
dihydrodichlorofluorescein diacetate (H2DCF-DA), and 
antibody against β-actin were obtained from Sigma-
Aldrich (St. Louis, MO). TNF-α was obtained from 
EMD Biosciences (La Jolla, CA). Antibody against Cav-
1 and p53 was obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Antibodies against peroxidase-labeled 
secondary antibody were obtained from Cell Signaling 
Technology (Boston, MA). 
Cell culture 
Human bronchial epithelial BEAS-2B cells were 
obtained from American Type Culture Collection (ATCC; 
Manassas, VA). Cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 
5% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
units/mL penicillin and 100 μg/mL streptomycin (Gibco, 
Gaithersburg, MA). Non-small cell lung cancer H460 
cells were obtained from ATCC and were cultured in 
RPMI 1640 medium supplemented with 5% FBS, 2 mM 
L-glutamine, and 100 units/mL penicillin/streptomycin. 
Both cells were maintained in a humidified atmosphere of 
5% CO2 at 37 °C.
Plasmid and transfection
Cav-1, p53, and control GFP plasmids were obtained 
from Invitrogen (Carlsbad, CA). Cells were transfected 
with Cav-1, p53, or GFP plasmid by nucleofection using 
Nucleofector® (Amexa Biosystems, Cologne, Germany), 
according to the manufacturer’s instructions. Briefly, 
cells were suspended in 100 μL of nucleofection solution 
with 2 μg of plasmid and nucleofected using the device 
program T020. The cells were then resuspended in 
500 μL of complete medium and seeded in 60-mm cell 
culture dishes. Cells were allowed to recover for 48 hours 
before each experiment and were cultured for 28 days in 
G418-containing medium (800 μg/mL). The pool stable 
transfectant was identified by Western blotting of Cav-1 
and p53 and was cultured in the G418-free medium for at 
least three passages before each experiment. 
Inhibition of Cav-1 by RNA interference
Lentiviral transduction particles carrying short 
hairpin RNA (shRNA) sequence against human Cav-1(5’-
CCGGGACGTGGTCAAGATTGACTTTCTCGAGAA
AGTCAATCTTGACCACGTCTTTTT-3’) and control 
nontarget sequence(5’-CCGGCAACAAGATGAAGAGC
ACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTT
TT-3’) were used to knockdown Cav-1 expression in BSW 
cells. The viral vectors were obtained commercially from 
Sigma (accession numbers NM_001753 and SHC002V) 
and were used according to the manufacturer’s instruction. 
Briefly, cells were seeded in 6-well plates (5×105/well) 
and incubated with Cav-1 shRNA lentiviral particles 
at the multiplicity of infection of 1.5 in the presence 
of hexadimethrine bromide (8 μg/mL) for 36 hours. 
Transfected cells were analyzed for Cav-1 by Western 
blotting prior to use. 
Chronic CNT exposure and derivation of CNT-
transformed cells
Non-tumorigenic human lung epithelial BEAS-
2B cells were continuously exposed to non-cytotoxic 
SWCNTs at 0.02 μg/cm2 in culture for 6 months. This 
dose, which is equivalent to a human lung burden for 8 
hours/day over a month at 400 μg/m3 (high CNT level 
reported in a research facility) [53] or about 3 years at 
10 μg/m3 (average CNT level in U.S. facilities) [54], was 
calculated from the lowest dose which induced positive 
in vivo biological response (10 μg/mouse lung). The cells 
were passaged weekly at preconfluent densities using a 
solution containing 0.05% trypsin and 0.5 mM EDTA 
(Invitrogen, Carlsbad, CA). SWCNT-exposed BEAS-
2B cells were designated as BSW cells. Parallel cultures 
grown in CNT-free medium with the same background 
level of dispersant provided passage-matched control and 
were designated as BC cells. After 6 months of exposure, 
the cells were cultured in normal complete medium, 
and their cancer and CSC phenotypes were assessed as 
described below.
Soft agar colony formation assay
Passage-control BC and chronic SWCNT-exposed 
BSW cells (3×104 cells) were mixed with culture medium 
containing 0.5% agar to a final agar concentration of 
0.33%. Cell suspensions were immediately plated onto 
dishes coated with 0.5% agar in culture medium. Colonies 
were examined under a light microscope after 2 weeks 
of culture. In order to assess the self-renewing property 
of cells, spheres were collected by gentle centrifugation, 
dissociated into single cell suspensions, filtered and 
cultured under conditions described above (second 
spheres).
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Tumor sphere assay
Tumor sphere assay was performed under non-
adherent and serum-free conditions as previously 
described as stem cell-selective conditions [24,25]. 
Briefly, cells were resuspended in 0.8% methylcellulose 
(MC)-based serum-free medium (Stem Cell Technologies, 
Vancouver, Canada) supplemented with 20 ng/mL 
epidermal growth factor (BD Biosciences, San Jose, 
CA), basic fibroblast growth factor and 4 mg/mL insulin 
(Sigma) and plated at 5×103 cells. Cells were then cultured 
for two weeks. 
Side population analysis and isolation
Cells were detached by trypsinization and 1×106 
cells were labeled with 5 μg/mL of Hoechst 33342 in 
DMEM-F12 medium containing 2% FBS in the presence 
or absence of 25 μM ABCG2 inhibitor fumitremorgin C 
(FTC; EMD Biosciences, San Diego, CA) at 37 °C for 90 
minutes. The cells were then centrifuged and resuspended 
in ice-cold Hank’s buffer salt solution (HBSS). Side 
population (SP) analysis and sorting were performed using 
BD FACSAria fluorescence-activating (flow cytometry)-
based cell sorter (FACS; BD Biosciences). The Hoechst 
dye was excited with a UV laser and its fluorescence was 
measured with both a 450/20 filter (Hoechst Blue) and 675 
LP filter (Hoechst Red). SP fraction was calculated based 
on the disappearance of SP cells in the presence of FTC 
using the formula: SP percentage in the absence of FTC − 
SP percentage in the presence of FTC. 
Hoechst uptake
Cells were directly stained with 5 μg/mL of Hoechst 
33342 in phosphate-buffered saline (PBS) in the culture 
plates at 37°C for 30 minutes. Hoechst 33342 blue uptake 
was analyzed by fluorescence microscope using a 350-nm 
excitation and 450-nm emission beam.
Cell migration and invasion assays
In vitro cell migration and invasion were determined 
using a 24-well Transwell® unit with polycarbonate 
(PVDF) filters (8-μm pore size). The membrane was 
coated with Matrigel® (BD Biosciences, NJ) for the 
invasion assay, while control inserts were used for the 
migration assay. Briefly, cells at the density of 3×104 cells 
per well (invasion) or 1.5×104 cells per well (migration) 
were seeded into the upper chamber of the Transwell® 
unit in serum-free medium. The lower chamber of the 
unit was filled with a normal growth medium containing 
5% FBS. Chambers were incubated at 37 °C in a 5% 
CO2 atmosphere for 48 hours. The non-migrating or non-
invading cells were removed from the inside of the insert 
with a cotton swab. Cells that migrated or invaded to the 
underside of the membrane were fixed and stained with 
10 μg/mL Hoechst 33342 for 30 minutes. Inserts were 
visualized and scored under a fluorescence microscope 
(Leica DM, IL). Cell migration and invasion was 
expressed as the ratio of migrated or invaded cells from 
the treated and control sample (relative level). 
Apoptosis assay
Apoptosis was determined by DNA condensation/
fragmentation assay using Hoechst 33342 dye. Cells were 
incubated with 10 μg/mL of Hoechst 33342 for 30 minutes 
and visualized under a fluorescence microscope (Leica 
Microsystems, Bannockburn, IL). Cells having intensely 
condensed and/or fragmented nuclei were considered 
apoptotic. Approximately 1000 nuclei from 10 random 
fields were analyzed for each sample. The apoptotic index 
was calculated as the percentage of cells with apoptotic 
nuclei over total number of cells. 
Whole genome expression microarray and gene 
ontology analysis
Whole genome expression was determined using 
high-throughput mRNA microarray analysis following 
MIAME guidelines as described previously [48]. Briefly, 
cells (1×106 in 6-cm plate) were lysed in triplicate using 
TRIzol® reagent (Life Technologies, Grand Island, NY), 
snap frozen in liquid nitrogen and shipped overnight to 
ArrayStar (Rockville, MD). Total RNA was isolated, 
purified and quantified using Nanodrop ND-1000 (Thermo 
Scientific, Rockford, IL). RNA was tested for purity 
and DNA contamination using A260/A280 ration and 
standard denaturing agarose gel electrophoresis. Gene 
expression profiling was performed using NimbleGen 
Human 12×135k Gene Expression Array using the 
NimbleGen Hybridization System (Roche NimbleGen, 
Madison, WI). The slides were scanned with Axon 
GenePix 4000B microarray scanner (Molecular Devices 
Corporation, Sunnyvale, CA). Raw data intensities were 
extracted from the aligned scanned images and normalized 
through quantile normalization and Robust Multichip 
Average method in NimbleGen v2.5. Gene level files 
were imported into Agilent GeneSpring GX (v12.1) for 
analysis. Genes with < 50.0 intensity were removed from 
further analysis. Volcano plots were constructed using 
two sample t-tests (p ≤ 0.05) and ± 2-fold change filter 
criteria to identify differentially expressed genes (DEGs) 
in chronic SWCNT-exposed BSW cells compare to 
control BC cells. All gene expression data were deposited 
to NCBI’s Gene Expression Omnibus and is accessible 
via accession number (GenBank ID: GSE56104). Gene 
ontology, gene network, and upstream prediction analysis 
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was performed using Ingenuity Pathway Analysis (IPA; 
Qiagen, Redwood City, CA).
ROS detection
ROS generation was determined fluorometrically 
using H2DCF-DA as a fluorescent probe. Briefly, cells 
were incubated with the probe (10 μM) for 30 min at 37°C, 
after which they were washed and resuspended in PBS, 
followed by analysis of cellular fluorescence intensity by 
a fluorescence plate reader at the excitation and emission 
wavelengths of 485 and 538 nm, respectively.
Western blot analysis
After specific treatments, cells were incubated 
in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 
1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM 
Na3VO4, 50 mM NaF, 100 mM phenylmethylsulfonyl 
fluoride, and a commercial protease inhibitor mixture 
(Roche Molecular Biochemicals, Indianapolis, IN) at 4 °C 
for 20 minutes. The lysate was collected and determined 
for protein content using the Bradford method (Bio-
Rad Laboratories, Hercules, CA). Proteins (40 μg) were 
resolved under denaturing conditions by 7.5-12% sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto nitrocellulose membranes 
(Bio-Rad). The transferred membranes were blocked for 
1 hour in 5% nonfat dry milk in TBST (25 mM Tris-HCl, 
pH 7.4, 125 mM NaCl, 0.05% Tween 20) and incubated 
with the appropriate primary antibodies at 4 °C overnight. 
Membranes were washed twice with TBST for 10 minutes 
and incubated with HRP-coupled isotype-specific 
secondary antibodies for 1 hour at room temperature. 
The immune complexes were detected by an enhanced 
chemiluminescence detection system and quantified using 
analyst/PC densitometry software.
Xenograft mouse model
Animal care and experimental procedures 
described in this study were performed in accordance 
with the Guidelines for Animal Experiments at West 
Virginia University with the approval of the Institutional 
Animal Care and Use Committee (IACUC #12-0502). 
Immunodeficient NOD/SCID gamma mice, strain NOD.
Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; Jackson Laboratory, 
Bar Harbor, ME), were maintained under pathogen-
free conditions within the institutional animal facility. 
Food and tap water were given ad libitum. Mice were 
subcutaneously injected with either 5×104 sorted SP/
NSP cells or 3×105 luciferase-labeled cells suspended 
in 100 μL of ExtraCel® hydrogel (Advanced BioMatrix, 
San Diego, CA). Mice were inspected daily for any 
signs of distress such as weight loss, hunching, failure to 
groom, and red discharge from the eyes. Tumor growth 
of luciferase-labeled cells was monitored weekly by 
using in vivo IVIS® imaging. At the end of experiments, 
mice were euthanized and tumors were dissected and 
weighted. Tumor specimens were cut into 5-μm sections 
and stained with hematoxylin and eosin (H&E) to confirm 
the cancer-specific morphology and cellular structure. 
Tumor metastasis to neighbor tissues was analyzed by 
IVIS® imaging after removal of primary SC tumors. All 
tissue sectioning and staining were performed at the West 
Virginia University Pathology Laboratory for Translational 
Medicine. 
Statistical analysis
The data represent means ± SD from three or more 
independent experiments as indicated. Statistical analysis 
was performed by Student’s t test at a significance level 
of p < 0.05.
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